Categories: News

Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, will report its fourth quarter and full year 2023 financial results on Monday, February 26, 2024, prior to the open of U.S. markets. Subsequently, at 8:30 am ET, the Company will host a webcast to discuss the financial results and provide a business update.

Investor Conference Call

The Company will host an investor webcast on Monday, February 26, 2024 at 8:30 am ET.

Investors and the general public can access the live webcast at https://www.webcaster4.com/Webcast/Page/3018/49928.

For those unable to listen to the live webcast, a replay will be available for 30-days on the Investors section of the Company’s website at www.krystalbio.com.

About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

CONTACT
Investors and Media:                                                             
Meg Dodge                                                      
Krystal Biotech                                                    
mdodge@krystalbio.com                                  

Staff

Recent Posts

Ro Weight Loss Announces Official Website Update Featuring Natural Daily Program for Medically-Guided Weight Management

Digital health platform offers FDA-approved treatments when appropriate and personalized care plans through licensed providers.New…

6 hours ago

NSCEB Announces Biotech Across America Roadshow, Makes First Stop in North Carolina

NSCEB is launching a 3-month tour of the booming U.S. biotechnology ecosystem  RALEIGH, N.C., June…

2 days ago

NextGen Healthcare Welcomes Madison Dearborn Partners as New Investment Partner and Announces Planned Leadership Succession

MDP Completes Acquisition of Significant Ownership Position in NextGen Healthcare and Partners with Thoma Bravo…

2 days ago

Rocketseed launches essential email signature guide for healthcare organizations

New resource helps healthcare providers improve branded communication, ensure HIPAA compliance, and boost patient engagement…

2 days ago

Hospital PMI® at 52%; May 2025 Hospital ISM® Report On Business®

TEMPE, Ariz., June 6, 2025 /PRNewswire/ -- Economic activity in the hospital subsector expanded in…

2 days ago